496 related articles for article (PubMed ID: 1709852)
21. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.
Holliday SM; Plosker GL
Drugs Aging; 1993; 3(3):278-99. PubMed ID: 8324301
[TBL] [Abstract][Full Text] [Related]
22. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
Fitton A; Faulds D; Goa KL
Drugs; 1992 Apr; 43(4):561-96. PubMed ID: 1377119
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients.
Gagiano CA; Müller PG; Fourie J; Le Roux JF
Acta Psychiatr Scand Suppl; 1989; 350():130-1. PubMed ID: 2530765
[No Abstract] [Full Text] [Related]
24. Efficacy in long-term treatment of depression.
Montgomery SA
J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
[TBL] [Abstract][Full Text] [Related]
25. An overview of paroxetine.
Boyer WF; Feighner JP
J Clin Psychiatry; 1992 Feb; 53 Suppl():3-6. PubMed ID: 1531819
[TBL] [Abstract][Full Text] [Related]
26. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
Wilde MI; Plosker GL; Benfield P
Drugs; 1993 Nov; 46(5):895-924. PubMed ID: 7507038
[TBL] [Abstract][Full Text] [Related]
27. Dothiepin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Lancaster SG; Gonzalez JP
Drugs; 1989 Jul; 38(1):123-47. PubMed ID: 2670509
[TBL] [Abstract][Full Text] [Related]
28. A risk-benefit assessment of mirtazapine in the treatment of depression.
Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
[TBL] [Abstract][Full Text] [Related]
29. [Antidepressants consumption in the global population in France].
Olié JP; Elomari F; Spadone C; Lépine JP
Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
[TBL] [Abstract][Full Text] [Related]
30. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline.
Kuhs H; Rudolf GA
Acta Psychiatr Scand Suppl; 1989; 350():145-6. PubMed ID: 2530773
[No Abstract] [Full Text] [Related]
31. Comparative efficacy of antidepressants.
Kasper S; Fuger J; Möller HJ
Drugs; 1992; 43 Suppl 2():11-22; discussion 22-3. PubMed ID: 1378369
[TBL] [Abstract][Full Text] [Related]
32. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat.
Chaput Y; de Montigny C; Blier P
Neuropsychopharmacology; 1991 Dec; 5(4):219-29. PubMed ID: 1839498
[TBL] [Abstract][Full Text] [Related]
33. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
Fabre LF
J Clin Psychiatry; 1992 Feb; 53 Suppl():40-3. PubMed ID: 1531823
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
[TBL] [Abstract][Full Text] [Related]
35. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Fawcett J; Barkin RL
J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
[TBL] [Abstract][Full Text] [Related]
36. Paroxetine: an update of its use in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
Drugs; 2002; 62(4):655-703. PubMed ID: 11893234
[TBL] [Abstract][Full Text] [Related]
37. A double-blind comparison of paroxetine, imipramine, and placebo in major depression.
Shrivastava RK; Shrivastava SH; Overweg N; Blumhardt CL
J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825
[TBL] [Abstract][Full Text] [Related]
38. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Lancaster SG; Gonzalez JP
Drugs; 1989 Feb; 37(2):123-40. PubMed ID: 2649353
[TBL] [Abstract][Full Text] [Related]
39. Paroxetine plasma levels: lack of correlation with efficacy or adverse events.
Tasker TC; Kaye CM; Zussman BD; Link CG
Acta Psychiatr Scand Suppl; 1989; 350():152-5. PubMed ID: 2530776
[No Abstract] [Full Text] [Related]
40. Milnacipran. A review of its use in depression.
Spencer CM; Wilde MI
Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
